Putting Pharmacogenetics into Practice

Pharmacogenetics has been suggested as the area of genetics with the most potential to rapidly provide public health benefits [1]. While early expectations of ‘tailor-made’ or ‘personalised’ medicines may have been over-hyped or even misleading and remain mostly unfulfilled, more modest benefits are still widely anticipated [2-4]. Here we assess progress in exploiting pharmacogenetics and current challenges for those attempting to put it into practice. This study is based on a comprehensive review of the industry and the science base in the USA, Europe and Japan as well as the institutional support frameworks needed for the development and use of genetic predictors of drug response in the EU and USA. The findings derive from a recently completed European Science and Technology Observatory (ESTO) study. The study used diverse methods including a range of publication and commercial database search strategies, online-surveys and in-depth interviews as the basis for its analysis.

HOPKINS Michael;  IBARRETA RUIZ Dolores;  GAISSER Sibylle;  ENZING Christien E.;  RYAN Jim;  MARTIN Paul A.;  LEWIS Graham;  DETMAR Symone;  VAN DEN AKKER-VAN MARLE Elske;  HEDGECOE Adam M.;  NIGHTINGALE Paul;  DREILING Marieke;  HARTIG K. Juliane;  VULLINGS Wieneke;  FORDE Tony; 

2006-11-09

NATURE PUBLISHING GROUP

JRC33980

https://publications.jrc.ec.europa.eu/repository/handle/JRC33980,